AACR 2026: Combo Therapies by Moderna, Marengo Show Promise in Skin, Breast Cancer

Why It Matters

These early combo signals could accelerate FDA Fast Track or breakthrough designations, potentially bringing more effective multi‑modal cancer treatments to patients faster. The mixed outcomes also illustrate the high risk‑high reward nature of combination development in oncology.

Key Takeaways

• Marengo's invikafusp + Trodelvy gave 40% response in 10 breast patients
• Moderna's mRNA‑4359 + Keytruda achieved 83% overall response in melanoma
• Akeso's cadonilimab + chemo gave 34% response, 96% control in pancreatic cancer
• Positive combo data could earn FDA Fast Track, speeding patient access
• Agenus's four‑drug regimen showed 0% response, underscoring combo risk

Pulse Analysis

The 2026 American Association for Cancer Research meeting underscored a decisive shift toward combination therapies as the cornerstone of modern oncology. Industry leaders are pairing precision immunotherapies with established modalities—such as antibody‑drug conjugates, chemotherapy, or checkpoint inhibitors—to overcome tumor heterogeneity and resistance. This strategic layering not only amplifies anti‑tumor activity but also aims to mitigate the toxicities associated with high‑dose monotherapies, positioning combos as the next logical evolution in drug pipelines.

Among the most compelling data were Marengo Therapeutics’ dual‑T‑cell agonist invikafusp alfa paired with Gilead’s ADC Trodelvy, which produced complete or partial responses in four of ten heavily pretreated metastatic breast cancer patients. Similarly, Moderna’s mRNA‑4359 antigen vaccine combined with Merck’s Keytruda yielded an 83% overall response rate in a small melanoma cohort, suggesting that mRNA‑based antigen delivery can synergize with checkpoint blockade to remodel the tumor microenvironment. These early signals are prompting companies to seek FDA Fast Track or breakthrough therapy designations, potentially compressing development timelines and delivering novel regimens to the clinic sooner.

However, the landscape remains fraught with uncertainty. Akeso’s cadonilimab‑chemo regimen demonstrated respectable efficacy in pancreatic cancer, yet an Agenus‑MiNK four‑drug cocktail failed to generate any responses in gastroesophageal adenocarcinoma, highlighting the complexity of multi‑agent interactions. Investors and regulators will scrutinize not only response rates but also durability, safety, and the ability to isolate each component’s contribution. As combination science matures, robust biomarker strategies and adaptive trial designs will be essential to de‑risk development and translate promising early data into definitive, practice‑changing therapies.